Why are some antibiotics approved in China but not the United States?

Antibiotic approval lists differ substantially across major regulatory bodies (U.S. FDA, EU EMA, China NMPA, others) based on country-specific risk-benefit assessments, antibiotic-resistance stewardship policies, and historical regulatory pathways. An antibiotic may be considered safe and effective in one country's regulatory framework while being either unapproved or deliberately restricted in another. The 2013 Hartz event involved antibiotics that are routinely approved for poultry use in China and the EU but not in the U.S., reflecting U.S. FDA's more restrictive antibiotic stewardship policy in food-producing animals.

How can I tell if a pet treat is made with U.S.-sourced ingredients?

Look for explicit "Made in the USA with U.S.-sourced ingredients" or "100% U.S. ingredients" labeling. "Made in the USA" alone is not sufficient because a U.S. manufacturer can use internationally-sourced ingredients in U.S. production. Brands committed to U.S. sourcing typically publish supplier transparency documentation, name specific ingredient suppliers, and audit supplier-side compliance with U.S. FDA approved-drug lists. International-sourced ingredients are not categorically risky — many internationally-sourced ingredients are produced under stricter quality systems than typical U.S. mass-market equivalents — but transparency lets owners make informed choices.

Hartz 2013 Chicken Chews Antibiotic Residue Recall

Q: Are trace antibiotic residues in pet treats a health risk?

Trace residue levels (parts per billion to low parts per million) are well below acute-toxicity thresholds for any FDA-relevant antibiotic. The theoretical concerns are (1) contribution to global antibiotic-resistance development if low-level exposure is sustained across many pets at population scale, and (2) rare allergic reactions in pets with antibiotic-specific hypersensitivity. Neither concern is clinically evident at the residue levels typical in international pet food sourcing events. U.S. FDA maintains zero-tolerance for unapproved antibiotic residues primarily as an antibiotic-resistance stewardship policy rather than an acute-safety policy.

Status: Resolved (precautionary, no illnesses). In January 2013, Hartz Mountain Corporation voluntarily withdrew approximately 20,000 packages of Hartz Chicken Chews and Hartz Oinkies Pig Skin Twists wrapped with Chicken after the company’s own testing detected trace amounts of unapproved antibiotic residue in the chicken ingredient sourced from China. The antibiotics involved are approved for poultry use in China and the European Union but not in the United States. No animal or human illnesses were reported.

What was recalled

In January 2013, Hartz Mountain Corporation voluntarily withdrew approximately 20,000 packages of two dog treat products: Hartz Chicken Chews and Hartz Oinkies Pig Skin Twists wrapped with Chicken. The withdrawal was triggered by the company’s own in-house quality-assurance testing, which detected trace amounts of antibiotic residue in the chicken-source ingredient used in both products.

The chicken in the recalled products was sourced from a supplier in China. The detected antibiotics are approved for poultry use in China and in European Union member states but are not among the antibiotics approved for poultry in the United States. This kind of regulatory-jurisdiction mismatch is a recurring issue in international pet food ingredient sourcing because antibiotic approval lists differ substantially across major regulatory bodies. Hartz Mountain’s withdrawal was precautionary — no animal or human illnesses were reported in connection with the trace residue levels detected. Veterinary Practice News coverage documented the supplier-sourcing pathway and the regulatory difference between U.S. and Chinese poultry antibiotic approval lists.

Why it was recalled

The 2013 Hartz event is structurally different from most pet food recalls because it involves a regulatory-jurisdiction mismatch rather than a contamination event. The trace antibiotic residue Hartz detected was the result of standard veterinary practice at the Chinese poultry supplier: those antibiotics are routinely used in Chinese poultry production with all required Chinese and EU regulatory approvals. The U.S. FDA, however, has not approved those specific antibiotics for use in poultry intended for the U.S. market, including poultry used as pet food ingredient. The detected residue levels were well below any acute-toxicity threshold, but the FDA enforces a zero-tolerance approach to unapproved drug residues in U.S.-marketed food (human or animal) regardless of demonstrated safety in other jurisdictions. Hartz’s decision to withdraw the affected lots reflects compliance with the FDA zero-tolerance policy rather than any documented acute health risk. Hartz subsequently revised its supplier qualification protocol to verify supplier-side antibiotic use against the U.S. FDA approved-drug list rather than relying solely on local-jurisdiction approval.

Health risks for your pet

No animal or human illnesses were reported in connection with the 2013 Hartz Chicken Chews withdrawal. The detected antibiotic residue levels were trace amounts well below any acute-toxicity threshold. The theoretical concern with chronic low-level antibiotic exposure through pet food includes: (1) contribution to global antibiotic-resistance development if exposure is sustained across many pets at population scale, and (2) very rare allergic reactions in pets with antibiotic-specific hypersensitivity. Neither concern was clinically evident at the residue levels and exposure durations involved in the 2013 Hartz event. The broader U.S. policy context: FDA has maintained zero-tolerance for unapproved antibiotic residues in food precisely to prevent the gradual normalization of low-level exposure that could contribute to long-term resistance development. The Hartz withdrawal is an example of the policy working as intended — the company’s own testing caught the residue, the affected product was removed, and Hartz revised its supplier qualification to prevent recurrence.

What to do if you bought affected product

All recalled Hartz product has long-expired Best Before dates; no household pantry should still contain affected packages. The lasting consumer-facing lesson is the importance of supplier-source transparency in pet treats and chews: brands that source ingredients from international suppliers (particularly China, given the documented regulatory differences) should publish their post-2013 supplier qualification protocols. Owners particularly concerned about international sourcing can look for treats marked as “Made in the USA” with U.S.-sourced ingredients, though these typically carry a 1.5-2x price premium over internationally-sourced equivalents. Hartz continues to produce a broad range of pet products and has not had a recall of this severity since 2013.

How this affects KibbleIQ’s grade

Hartz Mountain is not currently in the KibbleIQ scored database — the brand operates primarily in mass-market and chain-pet-retail channels with a product portfolio dominated by treats and accessories rather than complete-and-balanced pet foods. The 2013 antibiotic-residue event reflects the kind of supplier-side regulatory mismatch that is structurally difficult to prevent without explicit U.S.-approved-drug-list verification at the supplier qualification stage. Hartz’s in-house testing detected the issue before consumer illness emerged, and the company revised its supplier qualification protocol post-recall. Per our published methodology, treats and chews fall under our separate Treats Rubric v1.0 scoring; ingredient-source transparency and post-2013 supplier qualification documentation are quality-systems credits for any brand sourcing international ingredients.